36424 Federal Register / Vol. 63, No. 128 / Monday, July 6, 1998 / Notices

Name of Document Date of Issuance

Grouped by Intended

User or Regulatory

Activity

How to Obtain a Hard Copy of the Document (Name and Address, Phone, FAX, Email, or Internet)

Compliance Program 7348.808; Bioresearch

Monitoring; Good Laboratory Practices

(GLP) (Nonclinical)

August 8, 1994 FDA Staff Personnel Do

Food Laboratory Practice Program (Nonclinical Laboratories) 7348.808A: EPA Data

Audit Inspections

October 1, 1991 Do Do

Compliance Program 7348.810: Sponsors,

Contract Research Organizations and

Monitors

August 18, 1994 Do Do

Compliance Program 7348.809: Bioresearch

Monitoring; Institutional Review Board

August 18, 1994 Do Do

Compliance Program 7348.811: Bioresearch

Monitoring; Clinical Investigations

August 18, 1994 Do Do

VIII. International Conference on

Harmonization Guidances (CDER)

Name of Document Date of Issuance

Grouped by Intended

User or Regulatory

Activity

How to Obtain a Hard Copy of the Document (Name and Address, Phone, FAX, Email, or Internet)

E2B Data Elements for Transmission of Individual Case Safety ReportsJanuary 15, 1998 Regulated Industry Drug Information Branch (HFD–210), Center

for Drug Evaluation and Research, 5600

Fishers Lane, Rockville, MD 20857, 301–

827–4573 or Office of Communication,

Training, and Manufacturers Assistance

(HFM–40), Center for Biologics Evaluation

and Research (CBER), Food and Drug

Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 1–800–835–4709

or 301–827–1800, FAX Information System: 1–888–CBER–FAX (within the United

States)or 301–827–3844 (outside of the

United States and local to Rockville, MD).

Internet at http://www.fda.gov/cder/guidance/index.htm or http://www.fda.gov/cber/

publications.htm

E8 General Considerations for Clinical Trials December 17, 1997 Do Do

M3 Timing of Nonclinical Studies for the Conduct of Human Clinical Trials of PharmaceuticalsNovember 25, 1997 Do Do

QC3 Impurities; Residual Solvents December 24, 1997 Do Do

S1B Testing for Carcinogenicity of PharmaceuticalsFebruary 23, 1998 Do Do

S1C(R) Dose Selection for Carcinogenicity

Studies of Pharmaceuticals: Addendum on

a Limit Dose and Related Notes

December 4, 1997 Do Do

Dated: June 25, 1998.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 98–17702 Filed 7–2–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies, and Laboratories That Have

Withdrawn From the Program

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted
Federal Register / Vol. 63, No. 128 / Monday, July 6, 1998 / Notices 36425

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be identified as such at the end of the

current list of certified laboratories, and

will be omitted from the monthly listing

thereafter.

This Notice is now available on the

internet at the following website: http:/

/www.health.org

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh or Dr. Walter Vogl,

Division of Workplace Programs, 5600

Fishers Lane, Rockwall 2 Building,

Room 815, Rockville, Maryland 20857;

Tel.: (301) 443–6014.

Special Note: Our office moved to a different

building on May 18, 1998. The above

address is now the correct one to use for

all regular mail and correspondence. For

all overnight mail service use the

following: Division of Workplace

Programs, 5515 Security Lane, Room

815, Rockville, Maryland 20852.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

rounds of performance testing plus an

on-site inspection. To maintain that

certification a laboratory must

participate in a quarterly performance

testing program plus periodic, on-site

inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

ACL Laboratories, 8901 W. Lincoln

Ave., West Allis, WI 53227, 414–328–

7840 (formerly: Bayshore Clinical

Laboratory)

Aegis Analytical Laboratories, Inc., 345

Hill Ave., Nashville, TN 37210, 615–

255–2400

Alabama Reference Laboratories, Inc.,

543 South Hull St., Montgomery, AL

36103, 800–541–4931/334–263–5745

Alliance Laboratory Services, 3200

Burnet Ave., Cincinnati, OH 45229,

513–569–2051 (formerly: Jewish

Hospital of Cincinnati, Inc.)

American Medical Laboratories, Inc.,

14225 Newbrook Dr., Chantilly, VA

20151, 703–802–6900

Associated Pathologists Laboratories,

Inc., 4230 South Burnham Ave., Suite

250, Las Vegas, NV 89119–5412, 702–

733–7866/800–433–2750

Associated Regional and University

Pathologists, Inc. (ARUP), 500 Chipeta

Way, Salt Lake City, UT 84108, 801–

583–2787/800–242–2787

Baptist Medical Center-Toxicology

Laboratory, 9601 I–630, Exit 7, Little

Rock, AR 72205–7299, 501–202–2783

(formerly: Forensic Toxicology

Laboratory Baptist Medical Center)

Cedars Medical Center, Department of

Pathology, 1400 Northwest 12th Ave.,

Miami, FL 33136, 305–325–5784

Clinical Reference Lab, 8433 Quivira

Rd., Lenexa, KS 66215–2802, 800–

445–6917

Cox Health Systems, Department of

Toxicology, 1423 North Jefferson

Ave., Springfield, MO 65802, 800–

876–3652/417–269–3093 (formerly:

Cox Medical Centers)

Dept. of the Navy, Navy Drug Screening

Laboratory, P. O. Box 88–6819, Great

Lakes, IL 60088–6819, 847–688–2045/

847–688–4171

Diagnostic Services Inc., dba DSI, 4048

Evans Ave., Suite 301, Fort Myers, FL

33901, 941–418–1700/800–735–5416

Doctors Laboratory, Inc., P.O. Box 2658,

2906 Julia Dr., Valdosta, GA 31604,

912–244–4468

DrugProof, Division of Dynacare/

Laboratory of Pathology, LLC, 1229

Madison St., Suite 500, Nordstrom

Medical Tower, Seattle, WA 98104,

800–898–0180/206–386–2672

(formerly: Laboratory of Pathology of

Seattle, Inc., DrugProof, Division of

Laboratory of Pathology of Seattle,

Inc.)

DrugScan, Inc., P.O. Box 2969, 1119

Mearns Rd., Warminster, PA 18974,

215–674–9310

Dynacare Kasper Medical Laboratories,*

14940–123 Ave., Edmonton, Alberta,

Canada T5V 1B4, 800–661–9876/403–

451–3702

ElSohly Laboratories, Inc., 5 Industrial

Park Dr., Oxford, MS 38655, 601–236–

2609

Gamma-Dynacare Medical

Laboratories,* A Division of the

Gamma-Dynacare Laboratory

Partnership, 245 Pall Mall St.,

London, ON, Canada N6A 1P4, 519–

679–1630

General Medical Laboratories, 36 South

Brooks St., Madison, WI 53715, 608–

267–6267

Hartford Hospital Toxicology

Laboratory, 80 Seymour St., Hartford,

CT 06102–5037, 860–545–6023

LabCorp Occupational Testing Services,

Inc., 1904 Alexander Drive, Research

Triangle Park, NC 27709, 919–672–

6900/800–833–3984 (formerly:

CompuChem Laboratories, Inc.;

CompuChem Laboratories, Inc., A

Subsidiary of Roche Biomedical

Laboratory; Roche CompuChem

Laboratories, Inc., A Member of the

Roche Group)

LabCorp Occupational Testing Services,

Inc., 4022 Willow Lake Blvd.,

Memphis, TN 38118, 901–795–1515/

800–223–6339 (formerly:

MedExpress/National Laboratory

Center)

LabOne, Inc., 8915 Lenexa Dr., Overland

Park, Kansas 66214, 913–888–3927/

800–728–4064 (formerly: Center for

Laboratory Services, a Division of

LabOne, Inc.)

Laboratory Corporation of America, 888

Willow St., Reno, NV 89502, 702–

334–3400 (formerly: Sierra Nevada

Laboratories, Inc.)

Laboratory Corporation of America

Holdings, 69 First Ave., Raritan, NJ

08869, 800–437–4986/908–526–2400

(formerly: Roche Biomedical

Laboratories, Inc.)

Laboratory Specialists, Inc., 1111

Newton St., Gretna, LA 70053, 504–

361–8989/800–433–3823

Marshfield Laboratories, Forensic

Toxicology Laboratory, 1000 North

Oak Ave., Marshfield, WI 54449, 715–

389–3734/800–331–3734

MAXXAM Analytics Inc.,* 5540

McAdam Rd., Mississauga, ON,

Canada L4Z 1P1, 905–890–2555

(formerly: NOVAMANN (Ontario)

Inc.)

Medical College Hospitals Toxicology

Laboratory, Department of Pathology,

3000 Arlington Ave., Toledo, OH

43614, 419–381–5213

Medlab Clinical Testing, Inc., 212

Cherry Lane, New Castle, DE 19720,

302–655–5227

MedTox Laboratories, Inc., 402 W.

County Rd. D, St. Paul, MN 55112,

800–832–3244/612–636–7466

Methodist Hospital Toxicology Services

of Clarian Health Partners, Inc.,

Department of Pathology and

Laboratory Medicine, 1701 N. Senate

Blvd., Indianapolis, IN 46202, 317–

929–3587

Methodist Medical Center Toxicology

Laboratory, 221 N.E. Glen Oak Ave.,

Peoria, IL 61636, 800–752–1835/309–

671–5199

MetroLab-Legacy Laboratory Services,

1225 NE 2nd Ave., Portland, OR

97232, 503–413–4512/800–950–5295
36426 Federal Register / Vol. 63, No. 128 / Monday, July 6, 1998 / Notices

Minneapolis Veterans Affairs Medical

Center, Forensic Toxicology

Laboratory, 1 Veterans Drive,

Minneapolis, Minnesota 55417, 612–

725–2088

National Toxicology Laboratories, Inc.,

1100 California Ave. Bakersfield, CA

93304, 805–322–4250

Northwest Toxicology, Inc., 1141 E.

3900 South, Salt Lake City, UT 84124,

800–322–3361/801–268–2431

Oregon Medical Laboratories, P.O. Box

972, 722 East 11th Ave., Eugene, OR

97440–0972, 541–341–8092

Pacific Toxicology Laboratories, 1519

Pontius Ave., Los Angeles, CA 90025,

310–312–0056 (formerly: Centinela

Hospital Airport Toxicology

Laboratory.

Pathology Associates Medical

Laboratories, 11604 E. Indiana,

Spokane, WA 99206, 509–926–2400/

800–541–7891

PharmChem Laboratories, Inc., 1505-A

O’Brien Dr., Menlo Park, CA 94025,

650–328–6200/800–446–5177

PharmChem Laboratories, Inc., Texas

Division, 7610 Pebble Dr., Fort Worth,

TX 76118, 817–595–0294 (formerly:

Harris Medical Laboratory)

Physicians Reference Laboratory, 7800

West 110th St., Overland Park, KS

66210, 913–339–0372/800–821–3627

Poisonlab, Inc., 7272 Clairemont Mesa

Blvd., San Diego, CA 92111, 619–279–

2600/800–882–7272

Premier Analytical Laboratories, 15201

East I–10 Freeway, Suite 125,

Channelview, TX 77530, 713–457–

3784/800–888–4063 (formerly: Drug

Labs of Texas)

Presbyterian Laboratory Services, 5040

Airport Center Parkway, Charlotte, NC

28208, 800–473–6640/704–943–3437

Quest Diagnostics Incorporated, 4444

Giddings Road, Auburn Hills, MI

48326, 810–373–9120/800–444–0106

(formerly: HealthCare/Preferred

Laboratories, HealthCare/MetPath,

CORNING Clinical Laboratories)

Quest Diagnostics Incorporated,

National Center for Forensic Science,

1901 Sulphur Spring Rd., Baltimore,

MD 21227, 410–536–1485 (formerly:

Maryland Medical Laboratory, Inc.,

National Center for Forensic Science,

CORNING National Center for

Forensic Science)

Quest Diagnostics Incorporated, 4770

Regent Blvd., Irving, TX 75063, 800–

526–0947/972–916–3376 (formerly:

Damon Clinical Laboratories, Damon/

MetPath, CORNING Clinical

Laboratories)

Quest Diagnostics Incorporated, 875

Greentree Rd., 4 Parkway Ctr.,

Pittsburgh, PA 15220–3610, 800–574–

2474/412–920–7733 (formerly: MedChek Laboratories, Inc., Med-Chek/

Damon, MetPath Laboratories,

CORNING Clinical Laboratories)

Quest Diagnostics Incorporated, 2320

Schuetz Rd., St. Louis, MO 63146,

800–288–7293/314–991–1311

(formerly: Metropolitan Reference

Laboratories, Inc., CORNING Clinical

Laboratories, South Central Division)

Quest Diagnostics Incorporated, 7470

Mission Valley Rd., San Diego, CA

92108–4406, 800–446–4728/619–686–

3200 (formerly: Nichols Institute,

Nichols Institute Substance Abuse

Testing (NISAT), CORNING Nichols

Institute, CORNING Clinical

Laboratories)

Quest Diagnostics Incorporated, One

Malcolm Ave., Teterboro, NJ 07608,

201–393–5590 (formerly: MetPath,

Inc., CORNING MetPath Clinical

Laboratories, CORNING Clinical

Laboratory)

Quest Diagnostics Incorporated, 1355

Mittel Blvd., Wood Dale, IL 60191,

630–595–3888 (formerly: MetPath,

Inc., CORNING MetPath Clinical

Laboratories, CORNING Clinical

Laboratories Inc.)

Scientific Testing Laboratories, Inc., 463

Southlake Blvd., Richmond, VA

23236, 804–378–9130

Scott & White Drug Testing Laboratory,

600 S. 31st St., Temple, TX 76504,

800–749–3788/254–771–8379

S.E.D. Medical Laboratories, 500 Walter

NE, Suite 500, Albuquerque, NM

87102, 505–727–8800/800–999-LABS

SmithKline Beecham Clinical

Laboratories, 3175 Presidential Dr.,

Atlanta, GA 30340, 770–452–1590

(formerly: SmithKline Bio-Science

Laboratories)

SmithKline Beecham Clinical

Laboratories, 8000 Sovereign Row,

Dallas, TX 75247, 214–637–7236

(formerly: SmithKline Bio-Science

Laboratories)

SmithKline Beecham Clinical

Laboratories, 801 East Dixie Ave.,

Leesburg, FL 34748, 352–787–9006

(formerly: Doctors & Physicians

Laboratory)

SmithKline Beecham Clinical

Laboratories. 400 Egypt Rd.,

Norristown, PA 19403, 800–877–

7484/610–631–4600 (formerly:

SmithKline Bio-Science Laboratories)

SmithKline Beecham Clinical

Laboratories, 506 E. State Pkwy.,

Schaumburg, IL 60173, 847–447–

4379/800–447–4379 (formerly:

International Toxicology Laboratories)

SmithKline Beecham Clinical

Laboratories, 7600 Tyrone Ave., Van

Nuys, CA 91405, 818–989–2520 /

800–877–2520

South Bend Medical Foundation, Inc.,

530 N. Lafayette Blvd., South Bend,

IN 46601, 219–234–4176

Southwest Laboratories, 2727 W.

Baseline Rd., Tempe, AZ 85283, 602–

438–8507

Sparrow Health System, Toxicology

Testing Center, St. Lawrence Campus,

1210 W. Saginaw, Lansing, MI 48915,

517–377–0520 (Formerly: St.

Lawrence Hospital & Healthcare

System)

St. Anthony Hospital Toxicology

Laboratory, 1000 N. Lee St.,

Oklahoma City, OK 73101, 405–272–

7052

Toxicology & Drug Monitoring

Laboratory, University of Missouri

Hospital & Clinics, 2703 Clark Lane,

Suite B, Lower Level, Columbia, MO

65202, 573–882–1273

Toxicology Testing Service, Inc., 5426

N.W. 79th Ave., Miami, FL 33166,

305–593–2260

UNILAB, 18408 Oxnard St., Tarzana,

CA 91356, 800–492–0800/818–996–

7300 (formerly: MetWest-BPL

Toxicology Laboratory)

Universal Toxicology Laboratories, LLC,

10210 W. Highway 80, Midland,

Texas 79706, 915–561–8851/888–

953–8851

UTMB Pathology-Toxicology

Laboratory, University of Texas

Medical Branch, Clinical Chemistry

Division, 301 University Boulevard,

Room 5.158, Old John Sealy,

Galveston, Texas 77555–0551, 409–

772–3197

The following laboratory is

voluntarily withdrawing from the

National Laboratory Certification

Program on July 31, 1998: TOXWORX

Laboratories, Inc., 6160 Variel Ave.,

Woodland Hills, CA 91367, 818–226–

4373/800–966–2211 (formerly:

Laboratory Specialists, Inc.; Abused

Drug Laboratories; MedTox BioAnalytical, a Division of MedTox

Laboratories, Inc.)

*The Standards Council of Canada (SCC)

voted to end its Laboratory Accreditation

Program for Substance Abuse (LAPSA)

effective May 12, 1998. Laboratories, certified

through that program were accredited to

conduct forensic urine drug testing as

required by U.S. Department of

Transportation (DOT) regulations. As of that

date, the certification of those accredited

Canadian laboratories will continue under

DOT authority. The responsibility for

conducting quarterly performance testing

plus periodic on-site inspections of those

LAPSA-accredited laboratories was

transferred to the U.S. DHHS, with the

DHHS’’ National Laboratory Certification

Program (NLCP) contractor continuing to

have an active role in the performance testing

and laboratory inspection processes. Other

Canadian laboratories wishing to be

considered for the NLCP may apply directly

to the NLCP contractor just as U.S.

laboratories do. Upon finding a Canadian
Federal Register / Vol. 63, No. 128 / Monday, July 6, 1998 / Notices 36427

laboratory to be qualified, the DHHS will

recommend that DOT certify the laboratory

(Federal Register, 16 July 1996) as meeting

the minimum standards of the ‘‘Mandatory

Guidelines for Workplace Drug Testing’’ (59

Federal Register, 9 June 1994). After

receiving the DOT certification, the

laboratory will be included in the monthly

list of DHHS certified laboratories and

participate in the NLCP certification

maintenance program.

Richard Kopanda,

Executive Officer, Substance Abuse and

Mental Health Services Administration.

[FR Doc. 98–17846 Filed 7–2–98; 8:45 am]

BILLING CODE 4160–20–P

DEPARTMENT OF THE INTERIOR

National Recreation Lakes Study

AGENCY: National Recreation Lakes

Study.

ACTION: Notice of First Commission

Meeting, National Recreation Lakes

Study.

SUMMARY: The Omnibus Parks and

Public Land Management Act of 1996

authorizes a presidential commission to

review the demand for recreation at

Federal lakes, and to develop

alternatives for enhanced recreation

uses, primarily through innovative

public/private partnerships. This will be

the first meeting of the Commissionerdesignees and Staff.

DATES: July 20–21, 1998, starting at 8

a.m.

ADDRESSES: The briefing will be held at

the National Association Public

Administration Conference Room, First

Floor, 800 North Capitol Street, NW,

Washington, D.C. 20001. Please have

photo identification available for

admission into the building. The agenda

will consist of the following: SwearingIn Ceremony for Appointed

Commissioners; Election of a Vice

Chairman; Overview of the Status of

Recreation at Federal Lakes; Discussion

of Proposed Goals; Study Process/

Action Plan; Presentation of Findings

Reports; Subgroups & Topic Experts;

Communications Plan; Study Duration

& Report Due Date; Public Comment

Period; Necessary Decisions on Above

Agenda Topics; Future Meetings; Time

and Place of Next Meeting; and the

Adjournment.

FOR FURTHER INFORMATION CONTACT:

Jeanne Whittington, 202–219–7104.

Dated: June 30, 1998.

Jana Prewitt,

Executive Director, National Recreation Lakes

Study.

[FR Doc. 98–17961 Filed 7–2–98; 8:45 am]

BILLING CODE 4310–94–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Availability of the Draft

Environmental Assessment and Land

Protection Plan for the Proposed

Establishment of Swayze Lake

National Wildlife Refuge, St. Landry

Parish, LA

AGENCY: Fish and Wildlife Service,

Interior.

ACTION: Notice of availability of the

Draft Environmental Assessment and

Land Protection Plan for the Proposed

Establishment of Swayze Lake National

Wildlife Refuge.

SUMMARY: This notice advises the public

that the U.S. Fish and Wildlife Service,

Southeast Region, proposes to establish

a new national wildlife refuge in the

Swayze Lake area in St. Landry Parish,

Louisiana. The purpose of the proposed

refuge is to protect, enhance, and

manage a diversity of fish and wildlife

habitats in the Swayze Lake area for the

benefit of the area’s fishery, resident and

migratory waterfowl, shorebirds, wading

birds, neotropical migratory birds, the

federally listed Louisiana black bear,

and other native wildlife. A Draft

Environmental Assessment and Land

Protection Plan for the establishment of

the proposed refuge has been developed

by Service biologists in coordination

with the Louisiana Department of

Wildlife and Fisheries, the Natural

Resources Conservation Service, parish

officials, and other local entities. The

assessment considers the biological,

environmental, and socioeconomic

effects of establishing the proposed

refuge and evaluates three alternative

actions and their potential impacts on

the environment. Written comments or

recommendations concerning the

proposal are welcomed and should be

sent to the address given below.

DATES: Land acquisition planning for

the project is currently underway. The

draft environmental assessment and

land protection plan will be available to

the public for review and comment on

July 15, 1998. Written comments must

be received no later than August 14,

1998, in order to be considered for the

preparation of the final environmental

assessment.

ADDRESSES: Comments and requests for

copies of the draft environmental

assessment and for further information

on the project should be addressed to

Mr. Charles R. Danner, Team Leader,

Planning and Support Team, U.S. Fish

and Wildlife Service, 1875 Century

Boulevard, Atlanta, Georgia 30345, or by

telephone at 800/419–9582.

SUPPLEMENTARY INFORMATION: The

proposed refuge area consists primarily

of bottomland hardwoods, wooded/

shrub swamps, and other wetlands. It

covers a total of approximately 20,000

acres and is located within the

Atchafalya River Basin, about 5 miles

northwest of Krotz Springs in St. Landry

Parish, Louisiana. The Service proposes

to establish the refuge by purchasing

about 9,000 acres in fee title from

willing sellers. The remaining 11,000

acres would be sought through

conservation easements, cooperative

agreements, or fee title purchases,

depending on landowner willingness.

The Swayze Lake area is nationally

significant because it provides wintering

habitat for migratory waterfowl,

breeding habitat for wood ducks,

migration habitat for shorebirds and

neotropical migratory birds, and yearround habitat for wading birds. It is also

a feeding area for bald eagles. The

bottomland hardwoods also provide

important habitat for the federally listed

Louisiana black bear. Other resident

wildlife include the American alligator,

white-tailed deer, swamp rabbit, and

furbearers such as raccoon, mink,

muskrat, and otter.

The area’s freshwater fishery is

excellent. Numerous bayous and

backwater lakes are interspersed

throughout the area and provide

outstanding sportfishing opportunities.

Freshwater game species are abundant

and include largemouth bass, black and

white crappie, bluegill, and several

species of catfish. Crawfishing is also

extremely popular.

Dated: June 22, 1998.

Sam D. Hamilton,

Regional Director.

[FR Doc. 98–17724 Filed 7–2–98; 8:45 am]

BILLING CODE 4310–55–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[AK–962–1410–00–P]

Notice for Publication; Alaska Native

Claims Selection

In accordance with Departmental

regulation 43 CFR 2650.7(d), notice is

hereby given that decisions to issue

conveyance under the provisions of Sec.

14(h)(8) of the Alaska Native Claims

Settlement Act of December 18, 1971, 43

U.S.C. 1601, 1613(h)(8), will be issued

to the Bering Straits Native Corporation

for approximately 14,169 acres. The

lands involved are in the vicinity of Iron

Creek, Alaska, and are within T. 6 S., R.

30 W., Kateel River Meridian, Alaska.